Skip to main navigation
Pharming Group N.V. Logo
  • Home
  • News & Events
    News Releases Events and Presentations
  • Stock
    Stock Quote & Chart Analyst Coverage
  • Corporate Governance
    Documents & Charters Board of Directors Executive Committee Committee Composition
  • Financial Information
    SEC Filings Annual Reports Quarterly Results
  • Shareholder Services
    Investor FAQs Email Alerts Contact IR

News Releases

Mar 24, 2023
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and older Joenja® is expected to launch in the US in early April Pharming will host a
Feb 21, 2023
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands , Feb. 21, 2023 /PRNewswire/ -- Pharming Group N.V. (" Pharming " or "the Company") (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR)
Feb 16, 2023
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands , Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. (" Pharming " or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA)

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • Investor FAQs
  • © Pharming Group N.V. 2023